Loading…
Loading…
Electromed's direct-to-patient model, broad payer coverage, and disciplined sales execution support durable SmartVest growth. The bronchiectasis market remains substantially underpenetrated, leaving a long runway for greater HFCWO adoption. Hospital revenue is volatile, but the channel remains small and full-year hospital sales still increased.
Electromed, Inc. (ELMD) Q4 2026 Earnings Call Transcript
Electromed, Inc. (ELMD) came out with quarterly earnings of $0.39 per share, beating the Zacks Consensus Estimate of $0.32 per share. This compares to earnings of $0.25 per share a year ago.
NEW PRAGUE, Minn.--(BUSINESS WIRE)--Electromed Announces CEO's Planned Retirement.
NEW PRAGUE, Minn.--(BUSINESS WIRE)--Electromed, Inc. Announces Record Fiscal 2026 Fourth Quarter and Full Year Financial Results.
NEW PRAGUE, Minn.--(BUSINESS WIRE)--Electromed, Inc. to Report Q4 Fiscal 2026 Financial Results on August 25, 2026.
LQDA, FLXS, ELMD and AGX combine low beta, positive price momentum and strong fundamentals to help investors navigate market volatility.
Electromed (ELMD) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.